Although neurocognitive assessment can accurately detect the pattern and severity of cognitive impairment in patients with SUD, the administration of such an extensive neuropsychological assessment (NPA) is not always feasible. Often patients with SUD lack insight into their NCD, as indicated by a lack of correlation between objectively measured and subjectively experienced cognitive deficits (Horner, Harvey, & Denier, 1999 Walvoort, van der Heijden, Kessels, & Egger, 2016). Therefore, insight into an individual’s cognitive functioning is crucial, as it enables to personalize and optimize treatment effectiveness (Allen, Goldstein, & Seaton, 1997 Bates, Buckman, & Nguyen, 2013 Sofuoglu, Sugarman, & Carroll, 2010). The effects of chronic substance use on cognitive functioning are both acute and chronic and vary across substances, resulting in decreased treatment adherence, lower self-efficacy and less treatment retention (Aharonovich et al., 2006 Bates et al., 2006 Copersino et al., 2012). The exact prevalence of substance-induced NCD is, however, difficult to establish based on the existing literature (Toledo-Fernández et al., 2017).
Cognitive impairments in patients with SUD have an estimated prevalence of 30–80% (Copersino et al., 2009). DSM-5 American Psychiatric Association, 2013) introduced the term “neurocognitive disorder” (NCD) in which the subtype substance-induced NCD can be classified as either major or mild, based on severity and everyday limitations.
#MOCA MUSEUM VALIDATION MANUAL#
The Diagnostic and Statistical Manual of Mental Disorders (5th ed. SUD affects the individual in social, physical and economical ways (Laudet, Savage, & Mahmood, 2002) and may result in cognitive impairments interfering with treatment (Aharonovich et al., 2006 Bates, Pawlak, Tonigan, & Buckman, 2006 Copersino et al., 2012). While the MoCA can be used to screen for cognitive impairments in patients in addiction health care, the instrument’s sensitivity is not optimal, which should be taken into account when interpreting results.Ībout 0.6% of the adult population worldwide (an estimated 29.5 million) suffer from substance use disorder (SUD United Nations Office on Drugs and Crime, 2017). Furthermore, the relation between MoCA domain scores and the performance on their corresponding cognitive domain in the NPA is more reliable when the MoCA is administered at the same time as the NPA. Conclusion: While the MoCA is an adequate screen when administered at the same time as the NPA, the predictive validity of administering this cognitive screen at intake is limited. The criterion validity was determined predictively and concurrently, and sensitivities of. The most common primary substance of abuse was alcohol (70.7%). Results: Of all included patients, 54.9% were classified as having substance-induced neurocognitive disorder. Method: Eighty-two patients were assessed with two parallel versions of the MoCA at intake (baseline) and directly preceding an extensive neuropsychological assessment (NPA) approximately 8 weeks later (follow-up). Objective: The current study assessed the criterion validity of the Montreal Cognitive Assessment (MoCA) as a short cognitive screen for use in addiction health care.
0 kommentar(er)
